Your new post is loading...
REPORTS FULL-YEAR ADJUSTED EPS OF $3.32, UP 5.7 PERCENT; GAAP EPS $1.10- DELIVERS FOURTH-QUARTER ADJUSTED REVENUE OF $5.371 BILLION, UP 8.9 PERCENT OVER FOURTH-QUARTER 2013 (UP 5.1 PERCENT ON A REPORTED BASIS); GAAP REVENUE $5.452 BILLION- REVENUE GROWTH IN THE QUARTER REFLECTS 14.4 PERCENT GLOBAL OPERATIONAL SALES GROWTH FROM HUMIRA (UP 10.6 PERCENT ON A REPORTED BASIS) AND STRONG GROWTH FROM OTHER KEY PRODUCTS- DELIVERS ADJUSTED GROSS MARGIN IMPROVEMENT OF 410 BASIS POINTS IN THE FOURTH QUARTER- REPORTS FOURTH-QUARTER ADJUSTED EPS OF $0.89, UP 8.5 PERCENT; GAAP EPS ($0.51)- LAUNCHES INTERFERON-FREE HCV REGIMEN FOLLOWING APPROVAL IN UNITED STATES, EUROPE AND CANADA- CONFIRMS 2015 ADJUSTED EPS GUIDANCE RANGE, REFLECTING INDUSTRY-LEADING GROWTH VERSUS THE PRIOR YEAR
Global HUMIRA sales increased 10.6 percent, or 14.4 percent on an operational basis, excluding the impact of foreign exchange rate fluctuations.
Via Krishan Maggon
Humira with 2014 sales of $12.5 billion retains the top selling human medicine for the second year after the patent expiry of Lipitor.
Remicade
Rituxan
Avastin
Herceptin
are the other 5 top selling mabs in 2014.
to be updated
Humira with 2014 sales of $12.5 billion retains the top selling human medicine for the second year after the patent expiry of Lipitor.
Sovaldi
Remicade
Enbrel
Rituxan
Avastin
Herceptin
are the other top selling medicines in 2014.
to be updated